Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: Simultaneous Glucose Lowering and Renal Protection?

Canadian Journal of Diabetes

Volumn 38, Issue 5, 2014, Pages 356-363

  Cherney, David Z I ^a   Perkins, Bruce A ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Blood pressure; Hemodynamic function; Hyperfiltration; Hyperglycemia; Renin angiotensin aldosterone system; SGLT2 inhibition; Tubuloglomerular feedback; Type 1 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; PLACEBO; PRAMLINTIDE; REMOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GLYCEMIC CONTROL; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; INHIBITION KINETICS; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY BLOOD FLOW; NONHUMAN; RENAL PROTECTION; REVIEW; ULTRAFILTRATION; ANTAGONISTS AND INHIBITORS; BLOOD; CANADA; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE COURSE; DRUG EFFECTS; EPIDEMIOLOGY; GLOMERULUS FILTRATION RATE; KIDNEY FAILURE, CHRONIC; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CANADA; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERGLYCEMIA; KIDNEY FAILURE, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84923171176     PISSN: 14992671     EISSN: 23523840     Source Type: Journal    
DOI: 10.1016/j.jcjd.2014.05.006     Document Type: Review

References (70)

1. Peterson C. Analyse des phloridzins. Ann Acad Sci Francaise 1835, 15:178.
2. Ehrenkranz J.R., Lewis N.G., Kahn C.R., Roth J. Phlorizin: A review. Diabetes Metab Res Rev 2005, 21:31-38.
3. Shannon J.A., Smith H.W. The excretion of inulin, xylose and urea by normal and phlorizinized man. JClin Invest 1935, 14:393-401.
4. Ellsworth B.A., Meng W., Patel M., et al. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2. Bioorg Med Chem Lett 2008, 18:4770-4773.
5. Liu J.J., Lee T., DeFronzo R.A. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?. Diabetes 2012, 61:2199-2204.
6. Vestri S., Okamoto M.M., de Freitas H.S., et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. JMembr Biol 2001, 182:105-112.
7. Persson P., Hansell P., Palm F. Tubular reabsorption and diabetes-induced glomerular hyperfiltration. Acta Physiol (Oxf) 2010, 200:3-10.
8. Nordquist L., Brown R., Fasching A., et al. Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption. Am J Physiol Renal Physiol 2009, 297:F1265-F1272.
9. Vallon V., Richter K., Blantz R.C., et al. Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption. JAm Soc Nephrol 1999, 10:2569-2576.
10. Musso G., Gambino R., Cassader M., Pagano G. Anovel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med 2012, 44:375-393.
11. Stanton R.C. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: Is there a role for SGLT2 inhibitors in diabetic kidney disease?. Circulation 2014, 129:542-544.
12. Cherney D.Z., Perkins B.A., Soleymanlou N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type1 diabetes mellitus. Cardiovasc Diabetol 2014, 13:28.
13. Cherney D.Z.I., Perkins B.A., Soleymanlou N., et al. The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation 2014, 129:587-597.
14. Perkins B.A., Cherney D.Z., Partridge H., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 2014, 37:1480-1483.
15. Luippold G., Klein T., Mark M., Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012, 14:601-607.
16. Kim Y., Babu A.R. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012, 5:313-327.
17. Aschner P., Horton E., Leiter L.A., et al. Practical steps to improving the management of type 1 diabetes: Recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract 2010, 64:305-315.
18. Pilgrim J.L., Woodford N., Drummer O.H. Cocaine in sudden and unexpected death: A review of 49 post-mortem cases. Forensic Sci Int 2013, 227:52-59.
19. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEngl J Med 1993, 329:977-986.
20. George P., McCrimmon R.J. Potential role of non-insulin adjunct therapy in type 1 diabetes. Diabetic Med 2013, 30:179-188.
21. Cotroneo P., Manto A., Todaro L., et al. Hyperfiltration in patients with type I diabetes mellitus: A prevalence study. Clin Nephrol 1998, 50:214-217.
22. Bhat R., Bhansali A., Bhadada S., Sialy R. Effect of pioglitazone therapy in lean type 1 diabetes mellitus. Diabetes Res Clin Pract 2007, 78:349-354.
23. Nagai E., Katsuno T., Miyagawa J., et al. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus. Endocr J 2011, 58:869-877.
24. Whitehouse F., Kruger D.F., Fineman M., et al. Arandomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002, 25:724-730.
25. Ratner R., Whitehouse F., Fineman M.S., et al. Adjunctive therapy with pramlintide lowers HbA1C without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes 2005, 113:199-204.
26. Garg S.K., Moser E.G., Bode B.W., et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: Investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013, 19:19-28.
27. Kielgast U., Krarup T., Holst J.J., Madsbad S. Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 2011, 34:1463-1468.
28. Varanasi A., Bellini N., Rawal D., et al. Liraglutide as additional treatment for type1 diabetes. Eur J Endocrinol 2011, 165:77-84.
29. Shimada A., Shigihara T., Okubo Y., et al. Pioglitazone may accelerate disease course of slowly progressive type 1 diabetes. Diabetes Metab Res Rev 2011, 27:951-953.
30. Ellis S.L., Moser E.G., Snell-Bergeon J.K., et al. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: A pilot, double-blind, randomized, crossover trial. Diabet Med 2011, 28:1176-1181.
31. Jie W., Wang X., Zhang Y., et al. SDF-1alpha/CXCR4 axis is involved in glucose-potentiated proliferation and chemotaxis in rat vascular smooth muscle cells. Int J Exp Pathol 2010, 91:436-444.
32. Mudaliar S., Armstrong D.A., Mavian A.A., et al. Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care 2012, 35:2198-2200.
33. Rosenstock J JA, Wang F, Kim K, etal, for the EMPA-REG BASALTM Trial Investigators. Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2D). Paper presented at: Diabetes 2013, American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL; poster abstract 1102-P.
34. Wilding J.P., Norwood P., T'Joen C., et al. Astudy of dapagliflozin in patients with type2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656-1662.
35. Patrick A.W., Hepburn D.A., Swainson C.P., Frier B.M. Changes in renal function during acute insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabet Med 1992, 9:150-155.
36. Ele Ferrannini EM, Frascerra S, Baldi S, etal. Metabolic response to sodium glucose cotransporter 2 (SGLT2) inhibition with empagliflozin in patients with type 2 diabetes (T2DM). Paper presented at: Diabetes 2013, American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL; poster abstract 71-LB.
37. Najafian M., Jahromi M.Z., Nowroznejhad M.J., et al. Phloridzin reduces blood glucose levels and improves lipids metabolism in streptozotocin-induced diabetic rats. Mol Biol Rep 2012, 39:5299-5306.
38. Fujimori Y., Katsuno K., Ojima K., et al. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009, 609:148-154.
39. Cherney D.Z., Perkins B.A., Soleymanlou N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014, 129:587-597.
40. Rave K., Nosek L., Posner J., et al. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 2006, 21:2166-2171.
41. Guo R.X., Yang L.Z., Li L.X., Zhao X.P. Diabetic ketoacidosis in pregnancy tends to occur at lower blood glucose levels: Case-control study and a case report of euglycemic diabetic ketoacidosis in pregnancy. JObstet Gynaecol Res 2008, 34:324-330.
42. Burge M.R., Hardy K.J., Schade D.S. Short-term fasting is a mechanism for the development of euglycemic ketoacidosis during periods of insulin deficiency. JClin Endocrinol Metab 1993, 76:1192-1198.
43. Hostetter T.H., Olson J.L., Rennke H.G., et al. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981, 241:F85-F93.
44. Sugimoto H., Shikata K., Matsuda M., et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 1998, 41:1426-1434.
45. Ruggenenti P., Porrini E.L., Gaspari F., et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 2012, 35:2061-2068.
46. Magee G.M., Bilous R.W., Cardwell C.R., et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009, 52:691-697.
47. Wang T.T., Wu X.H., Zhang S.L., Chan J.S. Effect of glucose on the expression of the angiotensinogen gene in opossum kidney cells. Kidney Int 1998, 53:312-319.
48. Zatz R., Dunn B.R., Meyer T.W., et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. JClin Invest 1986, 77:1925-1930.
49. Sochett E.B., Cherney D.Z., Curtis J.R., et al. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. JAm Soc Nephrol 2006, 17:1703-1709.
50. The Microalbuminuria Captopril Study Group Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996, 39:587-593.
51. Barnett A.H., Bain S.C., Bouter P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. NEngl JMed 2004, 351:1952-1961.
52. Sasson A.N., Cherney D.Z. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 2012, 3:1-6.
53. Rahmoune H., Thompson P.W., Ward J.M., et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54:3427-3434.
54. Burgess E. Slowing the progression of kidney disease in patients with diabetes. JAm Soc Hypertens 2008, 2(Suppl):30-37.
55. Arakawa K., Ishihara T., Oku A., et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001, 132:578-586.
56. Thomson S.C., Rieg T., Miracle C., et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am JPhysiol Regul Integr Comp Physiol 2012, 302:R75-R83.
57. Kojima N., Williams J.M., Takahashi T., et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DM rats. JPharmacol Exp Ther 2013, 345:464-472.
58. Panchapakesan U., Pegg K., Gross S., et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy?. PLoS One 2013, 8:e54442.
59. Osorio H., Coronel I., Arellano A., et al. Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev 2012, 2012:542042.
60. Malatiali S., Francis I., Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008, 2008:305403.
61. Abdul-Ghani M.A., Norton L., Defronzo R.A. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011, 32:515-531.
62. Vallon V., Rose M., Gerasimova M., et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 2013, 304:F156-F167.
63. Vallon V., Schroth J., Satriano J., et al. Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus. Nephron Physiol 2009, 111:30-38.
64. Clar C., Gill J.A., Court R., Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012, 2:e001007.
65. List J.F., Woo V., Morales E., et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32:650-657.
66. Mithal A., Barnett A.H., Manassie J., et al. Empagliflozin in patients with type 2 diabetes mellitus (T2DM) and stage 3A, 3B and 4 chronic kidney disease (CKD). European Association for the Study of Diabetes (EASD) 2013, 23-27.
67. Yale J.F., Bakris G., Cariou B., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 15:463-473.
68. Cefalu W.T., Leiter L.A., Yoon K.H., et al. Canagliflozin demonstrates durable glycemic improvements over 104 weeks versus glimepiride in subjects with type 2 diabetes mellitus on metformin. Diabetes 2013, 62(Suppl 1A):LB65.
69. Pedersen M.M., Schmitz A., Pedersen E.B., et al. Acute and long-term renal effects of angiotensin converting enzyme inhibition in normotensive, normoalbuminuric insulin-dependent diabetic patients. Diabet Med 1988, 5:562-569.
70. Holtkamp F.A., de Zeeuw D., Thomas M.C., et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011, 80:282-287.